Bio-Works Technologies AB

Bio-Works Technologies operates in biotechnology. The company develops products that separate and purify molecules in the production of pharmaceuticals. The technology is based on chromatography, which is intended to handle the drug substance. Customers are found in the European market where the products are sold via distribution partners and to companies in the pharmaceutical industry, as well as research institutes and universities. The company was founded in 2006 and has its headquarters in Uppsala.

Quotes for Bio-Works Technologies AB

Board

CEO

  • Lone Carlbom

Chairperson of the Board

  • Peter Ehrenheim

Board

  • Jonas Ahlén
  • Andrea Ballagi
  • Eva Lindskog
  • Peter Nählstedt
  • Thomas Gür
** Powered by Modular Finance
*Powered by Modular Finance
Key Numbers
2026-03-31 2025-12-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31
Number of months that the report spans Q1 3 Months 2025 Q4 3 Months Q3 3 Months Q2 3 Months Q1 3 Months 2024
Total revenue MSEK 29.33 62.50 23.74 16.64 13.15 8.98 25.47
Earnings before interest and tax MSEK 4.19 -17.52 -0.90 -1.23 -7.58 -7.82 -38.00
Profit before tax MSEK 4.70 -17.16 -0.57 -1.36 -7.27 -7.97 -37.28
Net profit MSEK 4.68 -15.25 1.37 -1.37 -7.28 -7.98 -37.36
Earnings per share SEK 0.05 -0.17 0.01 -0.02 -0.09 -0.10 -0.75
Dividend per share SEK 0,00 0.00 0.00 0,00 0,00 0,00 0.00
Equity MSEK 55.02 49.21 49.21 30.04 29.84 36.47 44.58
Fixed assets MSEK 1.69 1.71 1.71 1.64 1.57 1.69 1.82
Intangible assets MSEK 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Current assets MSEK 68.85 69.05 69.05 50.93 48.98 54.07 50.68
Total asset MSEK 70.55 70.76 70.76 52.56 50.55 55.77 52.50
Long term liabilities MSEK 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Current liabilities MSEK 15.52 21.55 21.55 22.52 20.71 19.29 7.91
Number of shares SEK 99424593.00 98225122.00 98225122.00 80370942.00 78733461.00 77959580.00 77959580.00
*Compiled data from Millistream